

**Boston University
Journal of Science & Technology Law**

Symposium

Transgenic Agriculture: Biosafety and International Trade

Michael Baram, Calestous Juma,
Sheldon Krimsky, and Rufus C. King

Table of Contents

Speeches.....	[1]
Michael Baram.....	[1]
Calestous Juma.....	[10]
Sheldon Krimsky.....	[14]
Rufus C. King.....	[28]
Discussion Session.....	[34]

Transgenic Agriculture: Biosafety and International Trade[†]

Michael Baram, Calestous Juma,
Sheldon Krimsky, and Rufus C. King*

Michael Baram:¹

1. We stand at the threshold of a new century that will bring novel methods of producing foods, industrial materials, pharmaceuticals, and other products important to society and industry.² Today's session will, therefore, address a subject of great importance: the introduction of genetically modified crops, livestock, micro-organisms, and other substances into agriculture and related fields, made possible by American and foreign corporate biotechnology.

2. But these genetic advances and their potential benefits³ are not without controversy.⁴ Over the last few years, genetically-modified crops and

[†] © 1998 by the Trustees of Boston University; Boston University Journal of Science & Technology Law. Cite to this Symposium as 4 B.U. J. SCI. & TECH. L. 4 (1998). Pin cite using the appropriate paragraph number. For example, cite the first paragraph of this Symposium as 4 B.U. J. SCI. & TECH. L. 4 para. 1 (1998) (comments of Michael Baram). These proceedings are from the fourth session of the Biotech Law Symposium held at Boston University School of Law on April 17, 1997. For the proceedings of the other sessions, see 4 B.U. J. SCI. & TECH. L. 1-3 (1998). *Editor's note:* To aid the reader, the *Journal of Science & Technology Law's* staff has provided additional authority for the speakers' comments, referenced in the attached footnotes.

* *Editor's note:* Four persons originally participated in this Symposium. Because of unavailability prior to publication, the comments of one person, Mr. Richard Godown of BIO, have not been included.

¹ Michael Baram is a professor of law at Boston University School of Law. He is also the Director of the Boston University Center for Law and Technology.

² See Robert J. Frederick & Margaret Egan, *Environmentally Compatible Applications of Biotechnology*, 44 BIOSCIENCE 529, 529 (1994) (discussing uses of biotechnology in bioremediation, bioleaching, natural plastics, clean fuels, and agriculture).

³ See Cath Blackledge, *Genetic Science Know-How Will Determine Leadership in 21st Century*, Says Sykes, PHARMACEUTICAL BUS. NEWS, July 16, 1997, available in LEXIS, Market Library, PROMT File (discussing statements made by the chairman of Glaxo Wellcome about the future of the pharmaceutical industry); see also Steve Sternberg, *Prospecting or Modern Day Colonialism? Ethicists Examine Who Profits from Genetic Research*, BIOWORLD TODAY, May 8, 1996, available in 1996 WL 9518319.

microorganisms have moved from contained laboratories into commerce and the open environment.⁵ Despite testing and other assurances of their safety,⁶ there are persistent concerns and some research findings that such products pose threats to ecosystems and consumer health, and to the sustainable development aspirations of developing nations.⁷

3. Thus, concern about “biosafety” has arisen and poses complex issues in policy debates in the United States⁸ and abroad,⁹ in forums such as the United Nations (“UN”), the European Community,¹⁰ and various non-governmental organizations.¹¹

4. After talking with today’s speaker and panelists, I see four central issues for discussion. First, does transgenic agriculture pose foreseeable risks to the environment and human health? In addressing this issue, we need to consider recent

⁴ See Maurizio G. Paoletti & David Pimentel, *Genetic Engineering in Agriculture and the Environment: Assessing Risks and Benefits*, 46 *BIOSCIENCE* 665, 670-71 (1996) (listing the following “questionable uses of genetic engineering”: the use of growth hormones in dairy cattle, the use of microbes for pest control, and the release of genetically engineered organisms).

⁵ See *id.* at 665, 668 (citing 1993 Group of National Experts on Safety in Biotechnology, ANALYSIS OF FIELD RELEASE EXPERIMENTS (Organization for European Cooperation and Development, Paris, France) May 14, 1993 & Sept. 1993 update). Paoletti & Pimental also state that since 1992, more than 2000 genetically engineered plants have been released without any problem. See *id.* at 668.

⁶ See *id.* at 665 (explaining that genetic engineering and the use of transgenic species has reduced the time required to develop new crops and improve farming in developing countries).

⁷ See Michael Freemantle, *U.K. Panel Urges Gene Modification Protocol*, *CHEMICAL & ENGINEERING NEWS*, Feb. 5, 1996, at 9 (reporting an independent advisory panel’s warning that new rules are needed to avoid large scale environmental problems).

⁸ See generally Isaac Rabino, *What U.S. Researchers Think of Regulations and Regulators*, 14 *BIO/TECH.* 147, 147 (1996) (reporting that most U.S. researchers using recombinant DNA “would prefer a centralized unit to be responsible for regulating biotechnology”).

⁹ See Michael Baram, *LMO’s: Treasure Chest or Pandora’s Box?*, 104 *ENVTL. HEALTH PERSP.* 704 (1996). LMO’s are living modified organisms, a term used interchangeably with genetically modified organisms (GMOs).

¹⁰ See Brian Kirsop, *European Union’s Drive Toward a Single Market is Moving a Set of European Biotechnology Standards Nearer Completion*, *GENETIC ENGINEERING NEWS*, Sept. 15, 1997, available in 1997 WL 8970594 (reporting on the European Committee for Standardization’s efforts to form common standards for “biosafety, . . . containment of genetically manipulated organisms (GMOs), their release and marketing, and protecting the health and safety of workers using GMOs”).

¹¹ See Frederick & Egan, *supra* note 2, at 534 (listing international organizations that have established biotechnology regulations).

developments, such as the release of genetically modified microorganisms to combat pests and the harvest of genetically modified crops which are entering the food chain and now reach the dinner table.¹²

5. Second, biosafety in transgenic agriculture raises a number of critical risk management questions.¹³ If transgenic agriculture does present risks, are the risks manageable? Is risk management convenient and affordable for all nations, or does it require sophisticated technology and expertise available only to wealthy countries such as the United States? What steps need to be taken to shape individual and collaborative efforts to manage risk?

6. Several organizations have enacted guidelines for preventing biosafety problems. These guidelines address the technology itself, the need for public education, public involvement, and agricultural training, which raise the third important issue.¹⁴ Are the guidances sufficient and will they be followed?¹⁵ Regulation is not the easy answer from any standpoint. If regulation would be beneficial, should it be technical and prescriptive,¹⁶ an approach we seem to have abandoned in addressing other risks?¹⁷ Alternatively, should regulation focus on performance, with final outcome criteria, and thereby afford more flexibility to the

¹² See Paoletti & Pimentel, *supra* note 4, at 666 (discussing the introduction of new genes into crops and livestock).

¹³ See *id.* at 533-34 (discussing the need for regulation to control the risks associated with biotechnology and transgenic research); see also Ted Plafker, *First Biotech Safety Rules Don't Deter Chinese Efforts*, 266 SCIENCE 966, 966 (1994) (reporting on Chinese releases of transgenic plants and organisms into the environment).

¹⁴ See generally *Environmental Release of Genetically Engineered Organisms: Recasting the Debate*, GENEWATCH (Comm. for Responsible Genetics, Boston, Mass.), Mar.-June 1988, at 1, 2, reprinted in COUNCIL FOR RESPONSIBLE GENETICS, GENETIC ENGINEERING: UNRESOLVED ISSUES (1992).

¹⁵ See Rabino, *supra* note 8, at 147 (reporting researchers' opinions of various U.S. agencies' regulatory efforts).

¹⁶ See *id.* at 150 (stating that researchers favor risk assessments of their products instead of regulation of the processes used to develop the products); see also Paoletti & Pimentel, *supra* note 4, at 665 (asserting that U.S. deregulation of transgenic agriculture followed by the release of genetically engineered organisms into the wild would be a danger).

¹⁷ See *AGBIOTECH: USDA Simplifies Approval Rules*, APPLIED GENETICS NEWS, Sept. 1, 1997, available in LEXIS, Market Library, PROMT File (reporting amended regulations pertaining to procedures for obtaining non-regulation status of field tests of genetically engineered plants); see also Specification of Requirements and Procedures for Genetically Engineered Organisms, 60 Fed. Reg. 43,567, 43,567 (1995) (proposed Aug. 22, 1995) (proposing "to simplify procedures for the introduction of certain genetically engineered organisms").

regulated parties?¹⁸ Which institutions should be authorized to manage the risks?¹⁹ Should farmers and other members of the private sector be encouraged to self-regulate?²⁰ Should responsibility devolve to nations or to nongovernmental organizations?²¹ Overall, what infrastructure is needed to maximize the benefits and minimize the risks of this promising new area of technology?²²

7. Finally, there is the fourth issue to consider here: in addressing these technological and regulatory issues, can we also achieve results which are consistent with principles of free trade? Countries which support multilateral programs to address the risks of genetically engineered products might reconsider if the programs and strictures impair their ability to trade. And should trade be premised on technology transfer to developing nations, in order to develop their capacities and lessen their dependence on multinational biotech agriculture companies and western expertise - an issue that is likely to influence which nations support or reject any binding international agreements and subsequent regulations.

8. We have a most highly-qualified speaker to discuss these complex issues, Dr. Calestous Juma. Dr. Juma is a distinguished scholar, researcher, and author of many books and articles on biotechnology, agriculture, and biodiversity, and serves as Executive Secretary of the United Nations Convention on Biological Diversity ("CBD" or "Convention").²³ The Convention has been ratified by more than 150 nations, with the United States as one of the few non-ratifying countries.²⁴ The ratifying nations are now devoting their energies to establishing a biosafety protocol,

¹⁸ See Rabino, *supra* note 8, at 150 (stating researchers disfavor regulation of process).

¹⁹ See *id.* at 147-50 (discussing industry opinions of current institutional regulations).

²⁰ See Kathryn S. Brown, *Life on the Molecular Farm: Transgenic Plants Are Extending the Range of Chemical Production Possibilities in Agriculture*, 46 BIOSCIENCE 80, 83 (1996) (discussing the application of the USDA's easing of regulations for genetically engineered organisms and criticism that the move places too much responsibility in private hands).

²¹ See *id.*

²² See Paoletti & Pimentel, *supra* note 4, at 671 (concluding that transgenic agriculture has potential benefits, but without regulation and control, these benefits will be jeopardized).

²³ Convention on Biological Diversity, *opened for signature* June 5, 1992, 31 I.L.M. 818.

²⁴ See PARTICIPATION IN WORLD TREATIES ON THE PROTECTION OF THE ENVIRONMENT: A COLLECTION OF DATA 268-71 (Maria Clara Maffei et al. eds., 1997) (listing parties to the Convention on Biological Diversity).

that would be legally binding at the international level.²⁵ In directing the CBD, Dr. Juma's responsibilities are to protect global biodiversity and promote sustainable development. He now has the additional task of presiding over the CBD Working Group that is developing the biosafety protocol. We are honored to have him here.

9. Our panelists are also leaders in their respective fields. Professor Sheldon Krinsky is a risk policy analyst and biosafety specialist at Tufts University. He is also the author of illuminating books and reports on the subject of genetics and agriculture.²⁶ Rufus King is an attorney for biotechnology companies at the Boston law firm of Testa, Hurwitz & Thibault. Richard Godown represents BIO, the trade association of biotechnology companies.²⁷

Calestous Juma:²⁸

10. I am very happy to take this opportunity to share with you some of the developments that are taking place under the Convention. Before I get into the issues relating to the international regulation of biotechnology, I would like to spend a few moments giving you some background about the evolution of the concepts under the Convention. The United Nations has a long history of involvement with environmental issues through internal bodies such as the United Nations Environment Programme ("UNEP").²⁹ Indeed, the UNEP played a central role in facilitating the initial working papers and other materials that evolved into the text of the Convention.³⁰ In 1992, the United Nations sponsored the Conference on Environment and Development, known as the Earth Summit, in Rio de Janeiro, Brazil, to discuss a variety of issues that confront the threats to natural habitats

²⁵ See Convention on Biological Diversity, *supra* note 23, art. 28, 31 I.L.M. at 834; *U.N. Expert's Meeting Recommends Protocol on Genetically Modified Organisms*, [1995] 18 Int'l Env't Rep. (BNA) No. 16, at 599 (Aug. 9, 1995).

²⁶ See, e.g., SHELDON KRINSKY, *BIOTECHNICS AND SOCIETY: THE RISE OF INDUSTRIAL GENETICS* (1991); SHELDON KRINSKY & ROGER P. WRUBEL, *AGRICULTURAL BIOTECHNOLOGY AND THE ENVIRONMENT: SCIENCE, POLICY, AND SOCIAL ISSUES* (1996).

²⁷ *Editor's note*: Mr. Godown was unavailable prior to this publication, and his remarks have, therefore, been deleted.

²⁸ Calestous Juma is the Executive Secretary of the Convention on Biological Diversity.

²⁹ See *Biosafety Under the Biodiversity Convention* (visited Nov. 6, 1997) <<http://www.iisd.ca/linkages/vol09/0948003e.html>> (UNEP is also attempting to develop technical guidelines for biosafety).

³⁰ See Convention on Biological Diversity, *supra* note 23, 31 I.L.M. at 818 *microformed on* Readex No. [ST/]DPI/1307] (Dept. of Pub. Info.) (providing a brief history of the international efforts preceding the CBD's adoption).

and ecosystems. The Convention, a particularly important element of that Conference, is designed to look at ecological issues within a larger context.

11. The objectives of the Convention are both simple to express and difficult to achieve. To quote the Convention itself:

The objectives of this Convention, to be pursued in accordance with its relevant provisions, are the conservation of biological diversity, the sustainable use of its components and the fair and equitable sharing of the benefit arising out of the utilization of genetic resources, including by appropriate access to genetic resources and by appropriate transfer of relevant technologies, taking into account all rights over those resources and to technologies, and by appropriate funding.³¹

This single sentence embraces a primary concern for three issues which will take significant effort to reconcile in the real world: conserving the wealth of organisms and biological differences that exist on earth and intricately work together to make the planet fruitful and habitable; finding ways to continue to use the earth's resources in a environmentally sensitive and sustainable way; and determining an equitable way to share the benefits and control the risks of the technologies and human activities that exploit these resources.

12. The Earth Summit provided a focused opportunity for gathering nations to sign the Convention, which was signed by more than five times the minimum number required to begin future work on binding international agreements in this area.³² The parties to the CBD understood its role as an unprecedented initial step to greater international understanding and cooperation on issues that span the line between species and ecosystems. Consequently, the ratifying parties left the development of substantive rules used to guide scientific and economic issues to an *ad hoc* and ongoing Working Group.³³ This Working Group has met several times, and through a process of stating positions and discussion, has begun to develop a more common understanding of the elements that a binding international protocol on biological diversity should contain.³⁴ This work builds on a preliminary effort

³¹ See Convention on Biological Diversity, *supra* note 23, art. 1, 31 I.L.M. at 823.

³² See PARTICIPATION IN WORLD TREATIES ON THE PROTECTION OF THE ENVIRONMENT, *supra* note 24, at 268-71.

³³ See Convention on Biological Diversity, *supra* note 23, arts. 28-29, 31 I.L.M. at 834-35.

³⁴ See *Governments Start Talks on Biotechnology Safeguards* (visited Oct. 23, 1997) <<http://www.biodiv.org/press/pr7-96.html>> (releasing information about the meeting of the Working

made by a group of experts at the first meeting of the conference of parties to the CBD at Nassau, Bahamas, in December 1994.³⁵

13. One advantage within the Convention is that by establishing an ongoing Working Group to grapple with the technological and implementation issues that must be addressed in a protocol, the many diverse interested parties have an opportunity to observe the development of international law in this area.³⁶ Though openness may elicit disparate views on this subject from party and non-party nations, environmental groups, and members of related industries,³⁷ it also helps those working on the protocol to identify the most critical issues.³⁸ One hope is that this debate within the Working Group begins that path to consensus and concludes with a strong protocol that will not only protect current parties to the Convention, but will also attract a voluntary commitment to environmental health, technology security, and cooperation by non-parties.

Sheldon Krimsky:³⁹

14. I want to say a few words about the substantive body of issues that the Working Group and others have begun to address. Of particular concern are the genetically modified products that are emerging and the grassroots opposition to them in many countries.⁴⁰

Group at Aarhus, Denmark); *see also A Brief Analysis of the Meeting* (visited Oct. 18, 1997) <<http://www.mbnet.mb.ca/linkages/vol09/0948014e.html>> (describing some of the political alignments and negotiations at the Aarhus meeting, including initial attempts to determine what terms must be defined and agreed upon); *Consideration of the Priority Consensus Elements of the Madrid Meeting* (visited Oct. 18, 1997) <<http://www.iisd.ca/linkages/vol09/0948000e.html>> (noting progress on identifying a working structure for a protocol at the Working Group meeting in Madrid, Spain).

³⁵ See *U.N. Expert's Meeting Recommends Protocol on Genetically Modified Organisms*, *supra* note 25, at 599.

³⁶ See *id.*

³⁷ See generally *Structure of a Future Protocol* (visited Oct. 18, 1997) <<http://www.mbnet.mb.ca/linkages/vol09/0948009e.html>> (outlining the widely varying views on the shape of a biodiversity protocol).

³⁸ See *Biosafety Working Group Outlines Elements for Future Biodiversity Convention Protocol*, [1996] 19 Int'l Env't Rep. (BNA) No. 16, at 688 (July 23, 1996).

³⁹ Sheldon Krimsky is a professor in the Department of Urban and Environmental Studies at Tufts University.

⁴⁰ See *Consumers Differ On Acceptance of Genetically Modified Foods*, MILLING & BAKING NEWS, Mar. 25, 1997, available in LEXIS, News Library, MILBAK File (discussing the results of international consumer surveys about genetically engineered food and noting particularly strong opposition in northern Europe); *Coalition Seeks Labeling of Genetically Engineered Corn, Soybeans*;

15. Much of the controversy about biotechnology is focused in Europe, where some countries refuse to accept certain products, though they are willing to buy and use others.⁴¹ Considerable European opposition stems from a concern that the United States is merely using the World Trade Organization⁴² to pressure nations to accept American products without giving proper credence to European concerns.⁴³ Aside from the political misgivings these European countries have about allowing American products to enter their markets at all,⁴⁴ this contentious situation underscores the need to listen and address the risk management issues that accompany the advancement and increasing use of biotechnology.

16. In 1992, Dr. Calestous Juma was one of the cosigners and authors of a report by the International Service for National Agricultural Research (“ISNAR”).⁴⁵ The report was a first effort to articulate some of the problems in evaluating the biosafety of this new generation of products.⁴⁶ With no viable products on the

Launches Worldwide Boycott, FOOD LABELING NEWS, Oct. 10, 1996, available in LEXIS, Market Library, IACNWS File (reporting that 300 agricultural, health, and trade groups from 48 countries threatened a boycott to force major companies to label food products that use transgenic components).

⁴¹ See Julie Wolf, *Europe Turns Up Nose at Biotech Food*, WALL ST. J., Jan. 2, 1997, at 8 (noting that “only about 5% of foods made with genetically modified raw materials will have to be labeled as such under a new EU law”); Caroline Southey, *EU Agrees Rules For Genetically Engineered Foods*, FIN. TIMES, Dec. 2, 1996, at 20 (noting that the European Union labeling rules provide a “loophole . . . [for] oil made from genetically modified soybeans to be marketed without a special label . . . [and for] a mix of genetically engineered and conventional products to be imported without extra labels”).

⁴² The World Trade Organization is the successor to the General Agreement on Tariffs and Trade (GATT). See *FAQ* (visited June 3, 1998) <<http://www.wto.org/faqs/faq.html>>. The WTO is an “international agency overseeing the rules of international trade.” *Id.*

⁴³ See *U.S. Formally Protests EU Ban on Beef Treated With Hormones*, HOUSTON CHRON., May 9, 1996, at 4 (reporting that the U.S. filed formal charges with the World Trade Organization in hopes of forcing the European Union to repeal its ban on hormone-containing beef).

⁴⁴ See, e.g., Neil Buckley, *Brussels Defends Maize Ruling*, FIN. TIMES, Apr. 10, 1997, at 3 (reporting the conflict between the European Commission and the European Parliament over the importation of genetically modified corn, most of which would come from the United States); *U.S. Trade Report Singles Out Japan, EU, China for Criticism*, L.A. TIMES, Apr. 1, 1997, at D3 (noting U.S. Trade Representative Charlene Barshefsky’s concern that the EU has manifested “pervasive discrimination against U.S. agriculture exports”).

⁴⁵ G.J. PERSLEY ET AL., BIOSAFETY: THE SAFE APPLICATION OF BIOTECHNOLOGY IN AGRICULTURE AND THE ENVIRONMENT (1992).

⁴⁶ See *id.* at 1.

market at the time the report was published, it was mainly a theoretical exercise.⁴⁷ The report contained some of the central ambiguities and contradictions of our discourse on biotechnology.

17. One of the greatest tensions in that report, and in reality, is between power and risk. Some members of the biotechnology debate are caught in this dilemma by saying that the power of new biotechnology is unique but the risks are conventional. For example, the ISNAR report quoted a National Research Council publication that said, “The molecular methods have great power because they enable scientists to isolate genes and to transfer them across biological barriers.”⁴⁸ That statement emphasizes the uniqueness of gene splicing, but the authors diminish its importance by quoting from the same National Research Council document that says, “Crops modified by molecular and cellular methods should pose risks no different from those modified by classical genetic methods for similar traits.”⁴⁹ This creates a strange ambiguity. On one hand, it is alleged that we control this great power because we can cross species barriers, while on the other hand, we treat this power as if it is no different than traditional hybridization.

18. This false inference is often made because of confusion between precision and predictability. Recombinant DNA techniques are more accurate, or precise, than classical techniques for modifying organisms.⁵⁰ Simply because scientists have higher levels of skill at creating technological applications for the fields of biology and agriculture does not mean that they necessarily have the insight to foretell, or predict the consequences of the technology, such as the properties of a living modified organism.⁵¹ The result is an unfounded leap from understanding genotypes⁵² to thinking we understand phenotypes⁵³ to believing we can predict

⁴⁷ See *id.* at 5. But see *Biotechnology and Genetically Altered Foods: The Future is Now—What Will We Make of It?*, ENVTL. NUTRITION, Oct. 1, 1996, at S1, available in LEXIS, News Library, ASAPII File [hereinafter *The Future is Now*] (noting that the FDA approved rennet in 1990, the first biotechnology product produced by transgenic bacteria).

⁴⁸ PERSLEY ET AL., *supra* note 45, at 7 (quoting the National Research Council Report).

⁴⁹ *Id.* at 6.

⁵⁰ See *id.* at 3.

⁵¹ See *id.* at 4. Henry I. Miller consistently makes this error in *POLICY CONTROVERSY IN BIOTECHNOLOGY: AN INSIDER'S VIEW* (1997).

⁵² A *genotype* is “all or part of the genetical constitution of an individual or group.” MERRIAM WEBSTER'S COLLEGIATE DICTIONARY 487 (10th ed. 1994).

⁵³ A *phenotype* consists of “the visible properties of an organism that are produced by the interaction of the genotype and the environment.” *Id.* at 872.

ecological impacts.⁵⁴ There is no knowledgeable basis for moving from understanding genotypes to predicting ecological effects.⁵⁵ Simply predicting which genes are in the new organism does not provide a sound foundation for guessing the likely ecological effects of releasing that organism into the wild.⁵⁶ Nor does this intellectual leap identify the particular types of risks about which we should be concerned.⁵⁷

19. There are two types of risks in this area, which I call first- and second-order effects. Consider the implications of genetically modifying a plant. A first-order effect could be the creation of an ecological imbalance that adversely impacts humans or human systems, such as reducing the nutritional value of the transgenic plant.⁵⁸ Second-order effects are less direct. For example, they might occur when growing a genetically modified plant that is susceptible to pests and requires large amounts of a certain herbicide. Over use of the herbicide might cause weed resistance and eventually diminish the herbicide's utility.⁵⁹ Second-order effects often escape regulatory oversight in the United States. In reality, these two types of risks, and their effects, may overlap.

⁵⁴ See *EPA Recommended to Adopt a Process-Based Approach*, BIOTECH. BUS. NEWS, Feb. 25, 1994, available in LEXIS, Market Library, BIOBUS File (stating that recombinant DNA makes possible "novel genetic combinations [which] 'create uncertainties about how the gene will function and how its products may affect the phenotype and its impact upon the environment and human health.'").

⁵⁵ See *id.*

⁵⁶ See *id.*; see also MAE-WAN HO, GENETIC ENGINEERING: DREAM OR NIGHTMARE? (1998).

⁵⁷ For example, although some scientists suspected that herbicide-resistant crops might cause environmental problems, the nature of the trouble was not known in 1993. See *Transgenic Plants Pose Minimal Risk*, BIOTECH. BUS. NEWS, July 2, 1993, at 17, available in LEXIS, Market Library, BIOBUS File. Thus, initial reports suggested that transgenic plants posed little environmental risk because the herbicide-resistant crops were unlikely to develop the invasive properties of weeds. See *id.* Three years later, researchers found an environmental problem: the genetically engineered herbicide resistance may have spread to nearby weeds through ordinary cross-pollination. See *Herbicide Resistance Spreads to Weeds*, APPLIED GENETICS NEWS, Mar. 1, 1996, available in 1996 WL 8541653.

⁵⁸ The FDA must grant approval for the sale of a food product if its nutritional value as a transgenic food is outside of the normal range for the non-transgenic version. See *The Future Is Now*, *supra* note 47.

⁵⁹ See *Herbicide Resistance Spreads to Weeds*, *supra* note 57 (discussing Danish study about spread of genetically-engineered herbicide tolerance); see generally SHELDON KRIMSKY & ROGER P. WRUBEL, AGRICULTURAL BIOTECHNOLOGY AND THE ENVIRONMENT: SCIENCE, POLICY, AND SOCIAL ISSUES (1996).

20. A high profile example of a transgenic food issue is the bovine growth hormone used to stimulate milk production in dairy cows.⁶⁰ This example demonstrates our preoccupation with first-order effects without a commensurate concern for second-order effects. In the debate over the bovine growth hormone, proponents and opponents alike focused on its health effects for human cow-milk consumers.⁶¹ When the mainstream scientific community could not point to direct human health effects from the hormones,⁶² the hormones were permitted for use in American dairies⁶³ without any significant investigation of secondary effects on humans or animals. The necessary regulatory oversight was absent, failing even to insist that the public be informed about hormones through appropriate labeling.⁶⁴ Litigation will be the unfortunate result of this misunderstood and under-appreciated risk.

21. The risk assessment protocols that we have in the United States are woefully inadequate. What we have amounts to a voluntary system for assessing the risks of transgenic food. Companies that make new food products regulate themselves by comparing their products against certain guidelines issued by the Food and Drug Administration (“FDA”). If businesses decide that their genetically modified products and foods meet the guidelines, then they are free to produce, market, and sell their products without any significant governmental oversight.⁶⁵ The system relies on the corporations that produce genetically modified foods to identify to the FDA any products that are out of compliance with the most basic and routine safety regulations. The FDA does not conduct an analysis of every food product made by transgenic methods.⁶⁶ I think this failure to impose stricter

⁶⁰ See, e.g., Steven Pratt, *Growth Hormone for Dairy Cows Draws Concern*, CHI. TRIB., Dec. 16, 1993, at 48.

⁶¹ See Rogers Worthington, *To Dairy Industry, Hormone Top Issue*, CHI. TRIB., Jan. 7, 1990, at 21 (reporting that in Wisconsin, the debate had “shifted from health concerns to the consumer’s right to know” and that concerns about animal health and the economic survival of the small dairy farm had fueled the opposition).

⁶² See *International Dairy Foods Ass’n v. Amestoy*, 92 F.3d 67, 75 (2d Cir. 1996) (Leval, J., dissenting) (“Based on its study, the FDA authorized commercial use of rBST on November 5, 1993, concluding that ‘milk and meat from [rBST-treated] cows is safe’ for human consumption.”).

⁶³ See *id.* at 69-70.

⁶⁴ Cf. *The Future Is Now*, *supra* note 47 (“The FDA . . . does not require genetically altered foods to be labeled solely because they are genetically engineered.”).

⁶⁵ See *id.*

⁶⁶ See Statement of Policy for Regulating Biotechnology Products, 51 Fed. Reg. 23,309, 23,309 (1986); *The Future is Now*, *supra* note 47 (stating that the FDA uses a case-by-case approach). The

scrutiny comes from the initial false inference I mentioned.⁶⁷ I believe that the FDA assumes that when you put foreign genes into food, even if the genes cross species lines, the new variety is substantially equivalent to the old.⁶⁸ The FDA accepts, uncritically, the analogy between genetically modified food and hybridization of two crops in the same family.⁶⁹ Instead, genetic modification is much more like putting a peanut gene into a tomato than crossing two strains of corn.

22. As important as regulatory oversight of the production phase is, it should also be of concern that we have no systematic tests for evaluating the allergenicity of transgenic food products, a first-order effect that should provoke significant concern.⁷⁰ America does not have a single agency committed to testing for human allergic reactions to genetically modified food products.⁷¹ Human beings have an amazingly wide range of tolerance but also a wide range of allergies to plants that are used as foods.⁷² My concern is that when we begin mixing proteins across species lines, we could find that people will become allergic to some of the new foods.⁷³ Without testing, these effects can be unpredictable and deadly.⁷⁴

“FDA has determined that plant foods produced through biotechnology present no inherent risk and, therefore, should be regulated like any other food entering the marketplace,” meaning that only foods that meet certain criteria based on their characteristics, not how they were made, will be regulated. *See also Position of the American Dietetic Association: Biotechnology and the Future of Food*, 95 J. AM. DIETETIC ASS’N 1429, 1431 (1995) [hereinafter *Position of the American Dietetic Association*].

⁶⁷ See *supra* notes 58-59 and accompanying text.

⁶⁸ See Statement of Policy for Regulating Biotechnology Products, 51 Fed. Reg. at 23,312-13.

⁶⁹ See *id.*

⁷⁰ Ignorance of a food’s allergic effects is an important first-order concern because, without testing, it is impossible to tell to which foods people are allergic and what allergic reactions may result. See Rick Weiss, *Report Cites Risk of Allergic Reaction in Brazil Nut Gene-Engineered Soybean*, WASH. POST, Mar. 14, 1996, at A10; see also *Long March of the Tomato*, WASH. POST, May 21, 1994, at A22 (reporting on allergy concerns about the Flavr Savr tomato).

⁷¹ See Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed. Reg. 22,984, 22,985 (1992) (citing the FDA as the primary federal agency for regulating genetically altered food and the U.S. Department of Agriculture and the Environmental Protection Agency as secondary agencies).

⁷² See *id.* at 22,987 (“[O]nly a small fraction of the thousands of proteins in the diet have been found to be food allergens.”). Although approximately 1.5% of U.S. adults and 6% of U.S. infants have food allergies, most people develop a tolerance to the problematic foods. See *Food Allergy: Number of People With Food Allergies on the Rise*, DISEASE WKLY PLUS, Oct. 6, 1997, available in 1997 WL 13677901.

⁷³ See Statement of Policy: Foods Derived from New Plant Varieties, 57 Fed. Reg. at 22,987 (“FDA’s principal concern regarding allergenicity is that proteins transferred from one food source to

23. Another concern is that when plants are genetically modified by mixing proteins across species lines, some of the transferred proteins will come from bacterial genes.⁷⁵ That, too, may cause allergic responses. In addition, it may cause new types of antibiotic resistance, a second-order effect.⁷⁶

24. I propose that we need to know the full scope of the effects of transgenic agriculture before we encourage it. Simply guessing that a transgenic plant or product will be safe because the unmodified products were genetically safe, perhaps with minimal human allergenicity, is not an appropriate response to the potential risks. Today's trend in biotechnology is to treat our current food sources as the feed stock for a new food industry.⁷⁷ If this view is analogous to the evolution of the chemical industry, from the use of naturally occurring chemicals to the modern synthetic chemical production, then there will be an enormous exchange of proteins across all the food types.⁷⁸ Whether this is an expansion that people desire is another question altogether.⁷⁹

25. I recently spoke with a woman who is a member of the National Institute for Environmental Health Sciences.⁸⁰ She has worked on hormones throughout her

another . . . might confer on food from the host plant the allergenic properties of food from the donor plant.”); *Long March of the Tomato*, *supra* note 70 (noting that the introduction of new substances into foods could cause allergic responses in people because the foods need not be specially labeled).

⁷⁴ See Weiss, *supra* note 70 (noting that allergic reactions can range from “a rash to a life-threatening lung inflammation”); see also Beatrice Trum Hunter, *Put Down that Glass of Milk and Read This: Bovine Growth Hormone May Cause Allergies*, HEALTH NEWS & REV., Jan. 1, 1995, at 8 (discussing the possible adverse consequences for infants and adults from exposure to the bovine growth hormone in milk).

⁷⁵ *But cf. id.* (stating that bacteria genes rarely cause allergic reactions when used in genetically altered food).

⁷⁶ See *The Future is Now*, *supra* note 47 (explaining that pests may develop resistance to the toxins that were genetically engineered into plants to keep those insects away).

⁷⁷ See Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed. Reg. at 22,965.

⁷⁸ See KRIMSKY, *supra* note 26, at 98-99; see also Jane E. Brody, *A Cool Look at Genetically Altered Foods*, N.Y. TIMES, May 19, 1993, at C13 (discussing various naturally occurring proteins that may be added to food).

⁷⁹ See Mary Jane Angelo, *Genetically Engineered Plant Pesticides: Recent Developments in the EPA's Regulation of Biotechnology*, 7 U. FLA. J.L. & PUB. POLY 257, 288-90 (1996) (discussing public perceptions of biotechnology in food production); see also Karen Goldman Herman, Comment, *Issues in the Regulation of Bioengineered Food*, 7 HIGH TECH. L.J. 107, 111 (1992) (stating that negative public perception of bioengineered food may lead to tighter regulation).

⁸⁰ The National Institute for Environmental Health Sciences is one of the National Institutes for Health. See *NIEHS: Introduction* (visited June 4, 1998) <<http://www.niehs.nih.gov/external/intro.htm>>. The Institute attempts “to reduce the burden of

scientific career. When I asked her whether she would drink milk that was produced with bovine growth hormones, she emphatically said, "No," that she would choose milk without the hormone every time. Her decision was not based on any hard data, but rather a visceral feeling about the current state of events, which does not give individuals an opportunity to choose whether to accept exposure to unknown risks.⁸¹ The concern stems from private industry's control of research, development, and risk assessment of genetically engineered organisms, all without governmental oversight.⁸² I wonder how much confidence we can have in the data, which are not generally available to the public and are produced by the companies that own transgenic products. The question of trust should prompt us to consider whether we have a sufficient number of disinterested scientists to review these new products independently and to evaluate the industry's tests.⁸³

26. If these problems create significant and deep divisions in America, there is little doubt that we have a long way to go in proving the safety of transgenic products before the world community will accept them. American industry and policymakers must be more sensitive to the fact that opposition to American biotechnology from certain countries may not be based upon a well-defined and specific endpoint risk.⁸⁴ Rather, international distrust of American biotechnology stems from a logical reaction to a lack of vital information about the risks and benefits of genetically modified organisms and plants. The remedy for this distrust is to provide more information and enough time to understand and evaluate the data independently.

27. Food security is a pressing issue for many nations. When countries that face the brunt of food shortages and malnutrition show hesitance toward adopting the new technologies out of fear that they will jeopardize their fragile indigenous agricultural systems, the world, and especially the biotechnology producers, needs to pay close attention. People need sufficient time to understand what is happening to

human illness and dysfunction from environmental causes by understanding the interaction" of environmental factors, individual susceptibility, and age. *Id.*

⁸¹ See Interim Guidance on the Voluntary Labeling of Milk and Milk Products From Cows That Have Not Been Treated With Recombinant Bovine Somatotropin, 59 Fed. Reg. 6279, 6279-80 (1994).

⁸² See Amy Beth Goen, *Consumer Education Needed for Biofoods to Get to Market*, FOOD & DRINK DAILY, Jan. 26, 1993, available in 1993 WL 2792289 ("Most companies are honest, but given the current climate of public skepticism, the appearance of impropriety could prevent consumer acceptance of a new technology,' [Michael Phillips of the U.S. Congress Office of Technology Assessment] said.").

⁸³ See *id.*

⁸⁴ See Scott Kilman, *Europe Shifts Stance on Demand Over Genetically Altered Crops*, WALL ST. J., July 25, 1997, at A2 (explaining that European consumers are generally more apprehensive about genetically altered crops and labeling than Americans).

their food supply.⁸⁵ To transform the world's food supply, we will need a much better sense of the timing that it takes to do good risk assessment and the techniques required to evaluate whether these products will pose first or second order risks to the world community.

Rufus King:⁸⁶

28. As a lawyer who represents a number of small companies that are trying to make sense of the regulations that control genetically modified products, I am often in the position of having to explain the difference between the real and perceived risks that these products pose. As far as the Convention⁸⁷ is concerned, biological diversity, in the abstract, is something that people simply should support, just as they should support moderation of global warming or nuclear disarmament. At a local level, however, I believe that many people in the biotechnology industry are somewhat dismayed by the pictures of activist groups, such as Greenpeace, attempting to bar the importation of genetically modified products based on their concern for biological diversity.⁸⁸ Perhaps these activist groups do not understand the connections between these products and other pressing social issues.⁸⁹

29. Part of the reason that Americans may be more comfortable than our European trade partners with the idea of genetic modification is that Americans have been confronting and debating this issue far longer. A number of cases went through the federal courts in the United States in the early 1980s⁹⁰ and attempted to prevent field studies of these plants because the testing prior to their natural

⁸⁵ See Hunter, *supra* note 74, at 8 (noting that it takes years to study the incremental effects of genetically engineered food).

⁸⁶ Rufus King is a partner in the Boston law firm of Testa Hurwitz & Thibeault, LLP.

⁸⁷ See Convention on Biological Diversity, *supra* note 23, 31 I.L.M. 818.

⁸⁸ See *European Commission OKs Gene-Modified Corn*, MEALEY'S LITIG. REP.: BIOTECH., Dec. 31, 1996, at 9 (reporting that Greenpeace protesters had chained themselves to a French dock where modified corn would arrive).

⁸⁹ See, e.g., *id.* See also Paul B. Thompson, *Food Biotechnology's Challenge to Cultural Integrity and Individual Consent*, HASTINGS CTR. REP., July 17, 1997, at 34, available in 1997 WL 10124572 (reporting that ethical, cultural, and religious concerns have caused much controversy); *GREENPEACE: Legal Action Filed Against U.S. EPA Over its Approval of Genetically Engineered Plants*, M2 PRESSWIRE, Sept. 19, 1997, available in 1997 WL 14463385 (reporting that "green" groups believe that transgenic crops violate federal environmental, agricultural, and procedural laws and will cause significant human and environmental harm).

⁹⁰ See, e.g., *Foundation on Economic Trends v. Heckler*, 587 F.Supp 753, 755-57 (D.D.C. 1984), *vacated in part*, 756 F.2d 143 (D.C. Cir. 1985).

release violated the National Environmental Policy Act of 1969.⁹¹ As a result of this litigation, Congress held numerous hearings and debates to begin to understand the effect of releasing genetically modified organisms and to shape a pattern of regulation.

30. The American system of regulating biotechnology products is highly complicated, a virtual alphabet soup of state and federal agencies with overlapping authority. The FDA is one of the best-known agencies involved in biotechnology regulation. Under the Federal Food, Drug, and Cosmetic Act,⁹² the FDA has jurisdiction over all new foods and food additives to ensure that the products do not have any harmful qualities and are appropriately labeled.⁹³

31. The United States Department of Agriculture (“USDA”) has jurisdiction over plants that have the potential to become harmful, a “pest,”⁹⁴ in the natural environment.⁹⁵ The USDA carefully controls which companies can conduct field tests, how they carry out those tests, and how the tests assess for safety.⁹⁶ The USDA ultimately must grant approval for these products to enter interstate commerce.⁹⁷

32. The other major federal agency involved with transgenic agriculture is the Environmental Protection Agency (“EPA”). The federal Insecticide, Fungicide, and Rodenticide Act allows the EPA to regulate any product that has a pesticidal effect and does not come from a naturally occurring food source.⁹⁸ This brief description of

⁹¹ 42 U.S.C. § 4332 (1994).

⁹² Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-395 (1994).

⁹³ *See id.* §§ 341-350b (prohibiting the sale of unsafe foods and providing for more detailed regulation on relevant issues such as pesticide residues on food).

⁹⁴ *See id.* § 150aa(c) (defining a plant pest as “any living stage of: Any insects, mites, nematodes, slugs, snails, protozoa, or other invertebrate animals, bacteria, fungi, other parasitic plants or reproductive parts thereof, viruses, or any organisms similar to or allied with any of the foregoing, or any infectious substances, which can directly or indirectly injure or cause disease or damage in any plants or parts thereof, or any processed, manufactured, or other products of plants”).

⁹⁵ *See Plant Pests*, 7 U.S.C. §§ 150aa-jj (1994) (describing the USDA’s authority to regulate agriculture and plants generally).

⁹⁶ *See id.*

⁹⁷ 7 C.F.R. § 330 (1997).

⁹⁸ *See Environmental Pesticide Control Act*, 7 U.S.C. §§ 136-136y (1994) (governing the use and movement of pesticides).

federal regulation does not even come close to truly capturing the complexity and interconnectedness of the regulatory oversight.

33. Each state government provides its own additional overlay of regulation for this industry and its products. Given this convoluted arrangement, I would not necessarily advocate world-wide adoption of our regulatory scheme for other countries attempting to address risk management in the context of transgenic agriculture. What would be helpful however, is some level of international harmonization of regulation so that interaction between small, private companies and other countries is both productive and efficient.

Discussion Session

Michael Baram:

34. I think that the most immediate issue is labeling. As a consumer, I want to know what foods contain, and therefore be able to make an informed choice about what to eat. But this does not necessarily require government regulation if market forces are sufficient to make food producers and retailers voluntarily provide the desired information. For example, food is highly regulated by the Jewish community.⁹⁹ Before the mark signifying that a particular food is certified as consistent with the Jewish dietary laws, or kashruth, can be placed on the package, the religious authority must not only inspect the processing plant but also know every element in the end product.¹⁰⁰ Though there may be nothing inherently objectionable about genetically modified agricultural products from the perspective of Jewish dietary laws, the certifying religious authority must be assured that every component of the food meets that group's standards. Without clear labeling of seeds and resulting crops, these private groups cannot even begin to make an informed choice about what to certify. Thus, a niche market exists, and food companies competing for this market may opt for voluntarily providing the requisite information. The same can be said for other specialist markets, such as the organic food and "vegan" markets, and markets comprised of persons who have food allergies. So I raise the issue of whether market forces will cause private voluntary initiatives which will meet the call for labeling genetically modified foods, or whether government labeling and enforcement programs will be needed.

Sheldon Krimsky:

⁹⁹ See Beatrice Trum Hunter, *More Consumers Ask: Is it Kosher?*, CONSUMERS RES. MAG., Apr. 1, 1997, at 10, available in 1997 WL 10128557 (detailing contemporary controversies over kosher labeling).

¹⁰⁰ See Steven Anderson, *Kosher Tag Termed Sales Booster*, IDAHO BUS. REV., Apr. 6, 1998, at 7A, available in 1998 WL 9770016 (stating that the kosher food niche market is expanding for a variety of reasons associated with the perception that kosher food is safer and cleaner).

35. Going back to a point made earlier, I do not agree that the BSE experience can entirely account for Europe's objection to genetically modified plants, such as genetically engineered corn.¹⁰¹ I believe that the scientific committees in the European Union were justifiably concerned about the corn's impact.¹⁰² Yes, the corn was eventually approved, but the independent testing prior to marketing was not unwarranted.¹⁰³

Calestous Juma:

36. I am intrigued by your comment about the gap between public acceptance and scientific thought. This is quite reminiscent of the nuclear power debates where science did itself a disservice by staying entrenched and not addressing questions of public acceptability. Only when science becomes actively engaged in educating the public will international agreements follow because the many contentious issues are based on perception and not fact. My point is that though the public is dealing with biotechnology, it has the nuclear analogy in mind, even if it is not a good analogy. This reliance on the false analogy is particularly bothersome when the public must determine whether to trust scientific opinion because nuclear science is not the same as biological and genetic science.

Michael Baram:

37. I believe the last few comments indicate a widening gap between what science can establish and what the public perceives. With such a lack of consensus, how can courts deal with these problems? Being personally predisposed to concern about managing risk, I want to know what the risks are and how we can most effectively and reliably manage them based on scientific principles. Perception is not a rational basis for policy or regulation because it will vary based on dynamic social and cultural factors within each individual nation. Some countries will respect scientific rationality while others may give considerable weight to the views of emotional advocates or self-serving organizations. Without a scientific foundation, there will be no discipline or structure for appropriate resolution of these issues.

38. Professor Krimsky recently wrote an excellent paper which illustrates the indispensability of good science in policymaking.¹⁰⁴ In the paper, he discusses how to

¹⁰¹ See *supra* notes 88-89 and accompanying text.

¹⁰² See *European Commission Oks Gene-Modified Corn*, *supra* note 88, at 9.

¹⁰³ See *id.*; Elizabeth Wise, *EU on Verge of Allowing U.S. Corn Imports*, USA TODAY, Dec. 18, 1996, at 10B.

¹⁰⁴ See Sheldon Krimsky et al., *Standardized Microcosms in Microbial Risk Assessment*, 45 BIOSCIENCE 590, 592 (1995) (proposing that regulatory agencies, in collaboration with microbial

assess risk associated with the release of modified organisms to combat agricultural pests,¹⁰⁵ and carefully scrutinizes the limitations of our current risk management techniques.¹⁰⁶ Maybe Professor Krimsky could describe for us how close science is to accurately predicting whether release of a microorganism designed to kill a particular insect pest could create unintended ecological problems.

Sheldon Krimsky:

39. First, I must say that what I have written does not represent a consensus of scientific opinion. Depending on individual training and background, a scientist's perspective on risk and risk management could significantly diverge from others yet remain respectable within that scientist's own discipline and operating framework. Even within a single discipline, such as genetic research, scientists may differ on basic issues, such as the potential for harm. Despite this unsettled scientific opinion on transgenic risks, there has been progress in risk assessment through the use of microcosms.¹⁰⁷

40. By microcosms, I mean releasing complex and potentially underestimated microorganisms into the environment in stages and attempting to control risks at each stage.¹⁰⁸ Many people believe that this is one of science's riskiest moves, even riskier than introducing genetically modified plants into the environment.¹⁰⁹ The decision to use microcosms requires a complex understanding of the competitive advantages and disadvantages of modifying a microorganism and releasing it into the open environment.¹¹⁰

41. Risk assessment takes time and money. I predict that the government will have to support the standardization of microcosms before they can be a truly

ecologists, encourage the standardization of methods and procedures for using microcosms in risk assessment of genetically engineered microorganisms).

¹⁰⁵ *See id.*

¹⁰⁶ *See id.* at 595.

¹⁰⁷ *See id.* at 592 (noting that scientists have proposed microcosm studies as an effective means to predict the ecological effects of genetically engineered microorganisms before initiating field experiments).

¹⁰⁸ *See generally id.*

¹⁰⁹ *See id.* at 591 ("Once released, the microbes may establish and disperse in the environment becoming nearly impossible to eliminate.").

¹¹⁰ *See* Microbial Products of Biotechnology; Proposed Regulation Under the Toxic Substances Control Act, 59 Fed. Reg. 45,526, 45,526 (1994).

effective tool.¹¹¹ Neither the United States nor any other country has anything close at this time to standardized protocols for assessing the risk before release.¹¹² My coauthors and I advocate a canonical approach to the area of microcosm and microorganism research.¹¹³

42. Without standardization, businesses will continue to avoid developing and using genetically modified microorganisms to preserve their “all natural” image.¹¹⁴ Without further data on the risks and benefits of these new microorganisms, businesses have no reason to be confident in biotechnology or the public perception of biotechnology.¹¹⁵

Michael Baram:

43. Would it be accurate to say that microcosms are “virtual environments,” replicating the conditions of the open environment? Do these greenhouses allow scientists to sufficiently test and predict the interaction of the modified microorganisms in nature?¹¹⁶

Sheldon Krimsky:

44. That is a fairly accurate description. To create an effective, realistic microcosm, scientists take actual soil, plants, and other organisms from the planned release site. Because every ecological system is unique, this is a critical step.¹¹⁷ It would not be enough to use a standard soil environment, or the same plants, in every microcosm because that might not replicate the conditions of the release area.¹¹⁸

¹¹¹ See Krimsky et al., *supra* note 104, at 592 (stating microorganism study should be required for regulatory approval).

¹¹² See *id.* at 593 (stating that agencies base risk assessment on case-by-case experiments).

¹¹³ See *id.* at 597 (recommending regulatory authorities require microcosm data).

¹¹⁴ See, e.g., *Ice Cream—Ben & Jerry’s* (last modified June 3, 1998) <<http://www.benjerry.com>> (discussing that, although its dairy supplier has decided to allow the use of rGBH, Ben & Jerry’s remains committed to purchasing an rGBH-free dairy supply).

¹¹⁵ See *id.* (stating that 96% of people do not want to eat genetically altered foods because of recent food safety scares).

¹¹⁶ See Krimsky et al., *supra* note 104, at 594 (citing the ecological reality that microorganisms add to laboratory experiments).

¹¹⁷ See S.A. Bentjen et al., *Intact Soil-Core Microcosms for Evaluating the Fate and Ecological Impact of Release of Genetically Engineered Microorganisms*, 55 APPLIED & ENVTL. MICROBIOLOGY 198, 201 (1989).

¹¹⁸ See *id.*

The microcosm is important because the effects of releasing the modified microorganism directly into the environment are simply unknown.¹¹⁹

45. Technically, scientists take a core soil sample and place it in a containment frame. After injecting the modified microorganism into the soil sample, the scientists expose it to the same type of climate and moisture conditions as are present in the open environment.¹²⁰ During this time, the modified microorganism has a chance to settle, or act as it would outside of the microcosm.

Michael Baram:

46. Is there a quarantine period?

Sheldon Krimsky:

47. While the organism develops in the microcosm, scientists continue to take measurements. For example, they examine whether the modified microorganism might overtake the indigenous organisms in a way that would produce an ecological imbalance.¹²¹ Though there is no distinct quarantine period, the scientists using this controlled testing methodology would certainly have an opportunity to gauge an organisms's growth in an environment close to the one that nature provides.

Michael Baram:

48. Do you think this would be the surest way to proceed?

Sheldon Krimsky:

49. This process does assess risk by providing the modified microorganism an opportunity to behave as it would in nature. If the modified microorganism went wildly prolific, displacing all of the indigenous organisms, then scientists might decide that release is inappropriate. Or the microcosm might indicate that the modified microorganism is selectively disadvantageous to certain indigenous organisms, raising new considerations before release. I believe that this is a scientifically viable risk assessment method; nevertheless, before we trust the results of any one microcosm, we need to systematize the process.

Rufus King:

50. As a hypothetical problem, if microcosm studies fail to detect harmful side effects of genetically altered crops, the American legal system will not

¹¹⁹ Statement of Policy: Food Derived From New Plant Varieties, 57 Fed. Reg. 22,984, 22,985-87 (1992); Les Levidow, *The Oxford Baculovirus Controversy—Safely Testing Safety?*, 45 BIOSCIENCE 545, 549 (1995).

¹²⁰ See Krimsky et al., *supra* note 104, at 594.

¹²¹ See *id.*

necessarily be equipped to deal with the resulting harm. I am thinking of a scenario in which a single farmer chooses not to grow genetically modified crops because the local organic food cooperative will not recognize these plants as organic. All of the farmer's neighbors then plant genetically altered seeds which, in turn, create a group of pests that are resistant to whatever natural pest controls the local cooperative accepts. If the neighbors of those who planted these genetically altered plants suffered loss from these pesticide-resistant pests, they might have a suit in tort for defective product design or in contract for breach of warranty. Without clear scientific causation, however, the organic farmer probably will not be able to recover for pure economic loss unless he can show a preexisting duty.

Calestous Juma:

51. I agree that trade issues always play a role in these environmental debates. There is always a hope that international agreements dealing with the environment, such as the Convention, will be able to express a level of consensus on the trade issues that interact with science and the environment. And, should consensus ever develop on the trade issues, that will free international efforts to confront the more difficult scientific issues squarely.